Development and Validation of a Discriminating In Vitro Dissolution Method for Oral Formulations Containing Satranidazole

Table 8

Change in wavelength.

Time (minutes)	At 318	At 320	At 322
Average % release ± SD (𝑛=6)
0	0	0
5	8.95 ± 0.5456	85.12 ± 0.7678	83.98 ± 0.6789
10	34.01 ± 0.4345	98.23 ± 0.6678	97.31 ± 0.8012
15	44.25 ± 0.5987	99.81 ± 0.8978	98.12 ± 0.5612
30	66.87 ± 0.6745	101.29 ± 0.7809	99.24 ± 0.6769
45	77.12 ± 0.7568	76.84 ± 0.5982	77.46 ± 0.8145
60	85.93 ± 0.4768	87.09 ± 0.3780	85.76 ± 0.4568
Average at 60 min	86.26 ± 0.6744
% RSD at 60 min	0.839